BioSpace News Archive

Olink Holding AB announced its unaudited financial results for the fourth quarter ended December 31, 2023.

Olink Holding AB announced that the Annual Report for 2023 is now available on the Company’s website.

Emergent BioSolutions Inc. announced that the U.S. Food and Drug Administration has listed “No Action Indicated” or NAI status classification for the company’s Baltimore Bayview manufacturing facility.

Biosense Webster, Inc. announced the submission of the VARIPULSE™ Platform for Premarket Approval Application (PMA) to the U.S. Food & Drug Administration (FDA).

Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today the peer reviewed publication of Transforming Growth Factor Beta 2 (TGFB2) mRNA Levels, in Conjunction with Interferon-Gamma Receptor Activation of Interferon Regulatory Factor 5 (IRF5) and Expression of CD276/B7-H3, Are Therapeutically Targetable Negative Prognostic Markers in Low-Grade Gliomas: Past, Present, and Future Strategies in the Treatment and Management of Gliomas.

Scottish sensor technology scale-up Novosound has secured a patent for its ultrasonic instrumentation system, with the Dr Dave Hughes-led company recently launching its related Slanj platform targeted at the medical and wearable device sectors worldwide.

ZyVersa Therapeutics, Inc. reports financial results for full year ending December 31, 2023, and provides business update.

Neuronetics, Inc. announced clearance from the U.S. Food and Drug Administration (FDA) for NeuroStar Advanced Therapy for use as an adjunct for the treatment of major depressive disorder (MDD) in adolescent patients aged 15-21.

NRx Pharmaceuticals, Inc. today announced that Dr. Jonathan Javitt , Chairman and Chief Scientist of NRx Pharmaceuticals and co-CEO of HOPE Therapeutics, will present at the Ketamine 2024 Conference, which is planned for March 25-27, 2024.

AbbVie Inc. (NYSE: ABBV) (“AbbVie”) and Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos”) today announced a definitive agreement under which AbbVie will acquire Landos, a clinical stage biopharmaceutical company focused on the development of novel, oral therapeutics for patients with autoimmune diseases.